To print this article, all you need is to be registered or login on Mondaq.com.
Historically pharmaceutical companies turned to contract
manufacturers for achieving efficiencies in cost, capacity and
time-to-market, or to obtain specific expertise not available
in-house. However, the increment in outsourcing of manufacture is
driven, at least in part, by the fact that contract manufacturers
have increasingly developed innovative proprietary processes and
implemented technology that may well surpass that available at the
pharmaceutical client's own facilities. Moreover, nowadays few
pharmaceuticals are made in dedicated plants and key intermediates
and active compounds can be made in general-purpose plants.